Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin

Cancer Research

Volumn 56, Issue 21, 1996, Pages 4887-4890

  Gately, Stephen ^a   Twardowski, Przemyslaw ^a   Stack, M Sharon ^a   Patrick, Matthew ^a   Boggio, Lisa ^a   Cundiff, Deborah L ^a   Schnaper, H William ^a   Madison, Laird ^a   Volpert, Olga ^a   Bouck, Noel ^a   Enghild, Jan ^b   Kwaan, Hau C ^a   Soff, Gerald A ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NW Univ Feinberg School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; PLASMINOGEN;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR GROWTH;

ANGIOSTATINS; HUMANS; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE FRAGMENTS; PLASMINOGEN; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TUMOR CELLS, CULTURED;

EID: 10344247677     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. O'Reilly, M. S., Holmgren, L., Shing, Y, Chen, C, Rosenthal, R. A., Moses, M, Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
2. Sottrup-Jensen, L., Claeys, H., Zajdel, M., Petersen, T. E., and Magnusson, S. The primary structure of human plasminogen: isolation of two lysine-binding fragments and one "mini-" plasminogen (MW, 38,000) by elastase-catalyzed-specific limited proteolysis. In: J F. Davidson, R. M. Rowan, M. M. Samama, and P. C. Desnoyers (eds.), Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 3, pp. 191-209. New York: Raven Press, 1978.
3. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996
4. Soff, G. A., Sanderowitz, J., Gately, S., Verrusio, E., Weiss, I, Brem, S., and Kwaan, H C Expression of plasminogen activator inhibitor type I by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J. Clin. Invest., 96: 2593-2600, 1995.
5. Chen, C., Parangi, S., Tolentino, M J., and Folkman, J. A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res., 55: 4230-4233, 1995.
6. Castellino, F. J., and Powell, J. R Human plasminogen. Methods Enzymol., 80: 365-378, 1981.
7. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
8. Heussen, C., and Dowdle, E. B. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal. Biochem, 102: 196-202, 1980
9. Dameron, K. M., Volpert, O. V., Tainsky, M A, and Bouck, N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (Washington DC), 265: 1582-1584, 1994
10. Schnaper, H. W., Grant, D. S., Stetler-Stevenson, W. G., Fridman, R, D'Orazi, G., Murphy, A. N, Bird, R. E., Hoythya, M., Fuerst, T. R., French, D. L, Quigley, J. P., and Kleinman, H. K. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J. Cell Physiol., 156: 235-246, 1993.
11. Polverini P. J., Bouck, N. P., and Rastinejad, F. Assay and purification of naturally occurring inhibitor of angiogenesis. Methods Enzymol., 198, 440-450, 1991.
12. Dong, Z., Kumar, R, and Fidler, I. J. Generation of the angiogenesis inhibitor, angiostatin, by Lewis lung carcinoma is mediated by macrophage elastase. Proc. Am. Assoc. Cancer Res, 37: 58, 1996.
13. Folkman, J., and Shing, Y. Angiogenesis. J. Biol. Chem., 267: 10931-10934, 1992.
14. Takano, S., Gately, S., Neville, M. E., Herblin, W. F., Gross, J. L, Engelhard, H., Perricone, M., Eidsvoog, K., and Brem, S. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res, 54: 2654-2660, 1994.
15. Holmgren, L., O'Reilly, M S., and Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression Nat. Med., 1: 149-153, 1995.
16. Ware, J. L., and DeLong, E. R. Influence of tumor size on human prostate tumor metastasis in athymic nude mice. Br. J. Cancer, 51: 419-423, 1985
17. Smith, R C., Litwin, M. S., Lu, Y., and Zetter, B. R. Identification of an endogenous inhibitor of prostatic carcinoma cell growth. Nat. Med., 1: 1040-1045, 1995.
18. Gittes, R F. Carcinoma of the prostate. N Engl. J. Med., 324: 236-245, 1991